Immunome (IMNM) Receivables - Other (2022 - 2023)
Immunome (IMNM) posted Receivables - Other of $289000.0 for Q4 2023, up 38.94% on a QoQ basis from $208000.0 in Q2 2023, and down 65.88% year-over-year from $847000.0 in Q4 2022.
Immunome (IMNM) Receivables - Other (2022 - 2023) Analysis & Trends
Immunome's Receivables - Other history runs 2 years deep, the most recent figure standing at $289000.0 for Q4 2023.
- Quarterly Receivables - Other fell 65.88% year-over-year to $289000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $289000.0 (down 65.88% YoY) and the FY2023 annual result came in at $289000.0, down 65.88% from the prior year.
- Receivables - Other was $289000.0 for Q4 2023 at Immunome, up from $208000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $847000.0 in Q3 2022 and bottomed at $208000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immunome | 2.49 Bn | 1.91 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 289,000.00 |
| Dec 31, 2023 | 289,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Mar 31, 2023 | 821,000.00 |
| Mar 31, 2023 | 821,000.00 |
| Dec 31, 2022 | 847,000.00 |
| Dec 31, 2022 | 847,000.00 |
| Sep 30, 2022 | 847,000.00 |
| Sep 30, 2022 | 847,000.00 |
| Jun 30, 2022 | 800,000.00 |
| Jun 30, 2022 | 800,000.00 |